AHFS March 2025 Update | Pharmaceutical Press

This update contains 4 new monographs, 38 revised monographs and 23 discontinued Monographs.

New monographs: Crinecerfont; Landiolol Hydrochloride; Olezarsen Sodium; Remestemcel-L-rknd.

Revised monographs: Abacavir Sulfate; Benzgalantamine Gluconate; Cabotegravir and Rilpivirine; Cabotegravir, Cabotegravir Sodium; Crisaborole; Dapagliflozin Propanediol; Darbepoetin Alfa; Deutetrabenazine; Dolutegravir Sodium and Lamivudine; Doravirine; Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate; DULoxetine Hydrochloride; Duvelisib; Eculizumab; Emtricitabine; Etravirine; Fezolinetant; Fosamprenavir Calcium; Guselkumab; Iloprost (Frostbite); Lazertinib Mesylate; Lonapegsomatropin-tcgd; Lotilaner; Macitentan and Tadalafil; Mavacamten; Metoclopramide Hydrochloride; Nelfinavir Mesylate; Nirmatrelvir and Ritonavir; Ravulizumab-cwvz; Respiratory Syncytial Virus Vaccine; Respiratory Syncytial Virus Vaccine, Adjuvanted; Ribociclib Succinate; Selpercatinib; Sparsentan; Tipranavir; Velmanase Alfa-tycv; Voclosporin; Zuranolone.

Discontinued monographs: Aducanumab; Antiretroviral General Statement; Bamlanivimab and etesevimab; Bebtelovimab; Belladonna; Casirivimab and imdevimab; Cefotaxime; Ceftobiprole; Copanlisib; HMG-CoA Reductase Inhibitors General Statement; Infigratinib; Insulin detemir; Olaratumab; Omacetaxine; Oprelvekin; Peginterferon alfa-2b; Rosiglitazone; Sodium phenylbutyrate and taurursodiol; Sotrovimab; Tixagevimab and cilgavimab; Vitamins A and D; Vorapaxar; Voxelotor.